Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 380

Sort by

Sort Order Select

Journal Articles

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Blood (2020) 135 (16): 1396–1405.

https://doi.org/10.1182/blood.2019003526

Published: 2020

Includes: Supplemental data

Journal Articles

Predicting the future for DLBCL

Bruce D. Cheson

Blood (2020) 135 (16): 1308–1309.

https://doi.org/10.1182/blood.2020005002

Published: 2020

Journal Articles

Clinical Significance of Uptake Value on F18-FDG PET/CT and Histological Grade in 164 Patients with Follicular Lymphoma Including Transformation - a Single Center Retrospective Study

Mitsuhiro Yuasa, MD, Daisuke Kaji, MD, Kosei Kageyama, MD, Yuki Taya, MD PhD, Shinsuke Takagi, Hisashi Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD, Go Yamamoto, MD PhD

Blood (2019) 134 (Supplement_1): 1529.

https://doi.org/10.1182/blood-2019-130837

Published: 2019

Journal Articles

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Solomon A. Graf, MD, Ryan D. Cassaday, MD, Karolyn K. Morris, BA, Sanaz Behnia, MD, Qian Vicky Wu, PhD, Jenna M. Voutsinas, MPH, Ryan C. Lynch, MD, Elizabeth Krakow, MD, Heather A. Rasmussen, BS, Thomas R. Chauncey, MD PhD, Sandra Kanan, MSN, ARNP, Lorinda A. Soma, MD, Stephen D. Smith, MD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1596.

https://doi.org/10.1182/blood-2019-126086

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Jie Jin, MD PhD, Hongyan Tong, Yang Haiyang

Blood (2019) 134 (Supplement_1): 5387.

https://doi.org/10.1182/blood-2019-128171

Published: 2019

Journal Articles

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

Myrna Candelaria, MD PharmD, Adriana Palacios Campos, MD, Olga Gutierrez Hernandez, QFB, Alejandro Aviles, MD, Uvi Cancino-Ramos, MD, Lucia Taja Chayeb, PhD, Osvaldo García-Perez, MD, David Cantú de León

Blood (2019) 134 (Supplement_1): 5222.

https://doi.org/10.1182/blood-2019-125906

Published: 2019

Journal Articles

AVM0703, a New Treatment Option for Lymphoma Patients

Theresa Deisher, PhD, Margaret Taylor, Arya Ashok, PhD, Peter Jarzyna, PhD, Yumna Zahid, Stephanie Lee-Diaz, Colleen Rylatt, Kendra Poulin, Vaishnavi Parthasarathy

Blood (2019) 134 (Supplement_1): 5308.

https://doi.org/10.1182/blood-2019-128812

Published: 2019

Journal Articles

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Anna Guidetti, MD, Giulia Perrone, MD, Paola Coluccia, MD, Luca Fumagalli, MD, Anna Dodero, MD, Lucia Farina, MD, Flavio Arienti, MD, Filippo Bagnoli, MD, Luca Pappalettera, MD, Debora Degli Innocenti, Cristiana Carniti, PhD, Daniela Codazzi, MD, Paolo Corradini

Blood (2019) 134 (Supplement_1): 5619.

https://doi.org/10.1182/blood-2019-125286

Published: 2019

Journal Articles

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Leandro Cerchietti, MD, Giorgio Inghirami, MD, Nikita Kotlov, PhD, Viktor Svekolkin, PhD, Alexander Bagaev, PhD, Felix Frenkel, PhD, Maria Victoria Revuelta, PhD, Jude M Phillip, PhD, Maria Teresa Cacciapuoti, MS, Sarah C. Rutherford, MD, Peter Martin, FRCPC, MD MS, John P. Leonard, MD

Blood (2019) 134 (Supplement_1): 656.

https://doi.org/10.1182/blood-2019-128889

Published: 2019

Journal Articles

Myeloma Derived Extracellular Vesicles Containing Endoplasmic Reticulum Remodel the Bone Marrow Microenvironment Towards a Pro-Tumoral Senescent Phenotype

Yu Sun, BSc, MSc, PhD, Jayna J Mistry, BSc, Jamie A Moore, BSc, MSc, Charlotte Hellmich, MBBChir, Christopher R Marlein, PhD, Anna Haestier, Cesar A. Gomez, MD PhD FRCPath, Christopher J Morris, PhD, Kristian M Bowles, MBBS, PhD, Stuart A Rushworth, PhD

Blood (2019) 134 (Supplement_1): 689.

https://doi.org/10.1182/blood-2019-128268

Published: 2019

Journal Articles

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Giada Bianchi, MD, Peter G. Czarnecki, MD, Matthew Ho, PhD, Aldo M. Roccaro, MD PhD, Antonio Sacco, RN, Yawara Kawano, MD PhD, Anil Aktas Samur, PhD, Annamaria Gulla, MD, Tianzeng Chen, Kenneth Wen, Xinchen Wu, Yu-Tzu Tai, PhD, Gulden Camci-Unal, PhD, Irene M. Ghobrial, MD, Ruben D. Carrasco, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 507.

https://doi.org/10.1182/blood-2019-128778

Published: 2019

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All- Trans retinoic Acid (ATRA) through the Transcription Factor CREB

Blood (2019) 134 (Supplement_1): 1692.

https://doi.org/10.1182/blood-2019-128573

Published: 2019

Journal Articles

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Toshiki Terao, MD, Yoichi Machida, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Kentaro Narita, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1861.

https://doi.org/10.1182/blood-2019-130845

Published: 2019

Journal Articles

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Pamela Allen, MD MSc, Hatice Savas, MD, Andrew M. Evens, DO,MSc, Barbara Pro, MD, Reem Karmali, MD, Brett Alan Palmer, BS, Eric Mou, MD, Jeffrey Bearden, BA, Denise M Scholtens, PhD, Gary Dillehay, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2019) 134 (Supplement_1): 235.

https://doi.org/10.1182/blood-2019-123906

Published: 2019

Journal Articles

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Nicole Sunseri, MD PhD, Xiufen Chen, PhD, Noemie Wald, PhD, Julie Preillon, PhD, Sonali M. Smith, MD, Gregory Driessens, PhD, Justin Kline, MD

Blood (2019) 134 (Supplement_1): 391.

https://doi.org/10.1182/blood-2019-131493

Published: 2019

Journal Articles

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Akihiro Kitadate, MD PhD, Kentaro Narita, MD, Kota Fukumoto, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Hiroki Kobayashi, MD, Yoshiaki Abe, MD, Daisuke Miura, MD, Masami Takeuchi, MD, Youichi Machida, MD, Naoto Takahashi, MD PhD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 2839.

https://doi.org/10.1182/blood-2019-122799

Published: 2019

Journal Articles

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Conrad-Amadeus Voltin, Jasmin Mettler, MD, Horst Mueller, PhD, Michael Fuchs, MD, Christian Baues, MD, Markus Dietlein, MD, Andreas Engert, MD, Peter Borchmann, MD PhD, Carsten Kobe, Paul J Bröckelmann, MD

Blood (2019) 134 (Supplement_1): 4020.

https://doi.org/10.1182/blood-2019-123641

Published: 2019

Journal Articles

Mutational Landscape, Copy Number Alterations and Tumor Burden Assessed By Cell-Free DNA in Diffuse Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 4110.

https://doi.org/10.1182/blood-2019-128813

Published: 2019

NARROW

High total metabolic tumor volume at baseline predicts survival independent of response to therapy

Predicting the future for DLBCL

Clinical Significance of Uptake Value on F18-FDG PET/CT and Histological Grade in 164 Patients with Follicular Lymphoma Including Transformation - a Single Center Retrospective Study

Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Combination of Tigecycline and Homoharringtonine Synergistically Enhances Anti-Leukemia and Anti-MDS Effect Followed By Inhibiting Mitochondrial Translation through AKT/Mtorpathway and Downregulation of Anti-Apoptotic Proteins

Impact of the Association between Tgl and EZH2 Mutations (Y641N/Y641F/Y641H/Y641S) on Disease Free Survival of Patients with Diffuse Large B-Cell Lymphoma

AVM0703, a New Treatment Option for Lymphoma Patients

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Microenvironmental Signatures Reveal Biological Subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) Distinct from Tumor Cell Molecular Profiling

Myeloma Derived Extracellular Vesicles Containing Endoplasmic Reticulum Remodel the Bone Marrow Microenvironment Towards a Pro-Tumoral Senescent Phenotype

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Depletion of the Long Non-Coding RNA MALAT1 primes Chronic Myelomonocytic Leukemia (CMML) for Differentiation Therapy with All- Trans retinoic Acid (ATRA) through the Transcription Factor CREB

Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis in Multiple Myeloma and Stratification of Revised International Staging System Stage II

Brief Pembrolizumab(PEM) Monotherapy Results in Complete and Near Complete Responses in the Majority of Untreated Patients with Classical Hodgkin Lymphoma (cHL): A Multicenter Phase 2 PET-Adapted Study of Sequential PEM and AVD

Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL

Baseline Total Lesion Glycolysis Combined with Interim PET/CT Is a Robust Predictor of Outcome in Patients with Peripheral T-Cell Lymphoma

Metabolic Tumor Volume for Early Response Assessment in Early-Stage Unfavorable Hodgkin Lymphoma Treated with Nivolumab in the GHSG Nivahl Phase II Trial

Mutational Landscape, Copy Number Alterations and Tumor Burden Assessed By Cell-Free DNA in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only